MedTrace Logo

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25682

Last updated 2017-06-09

Study results available
· View outcomes & findings →

Summary

The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents. Similar analysis will be conducted in a smaller cohort of bare metal coronary stent - treated subjects.

Conditions

Interventions

DRUG

Placebo & Aspirin

DRUG

Clopidogrel & Aspirin, Prasugrel & Aspirin

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Sanofi-Synthelabo

    collaborator INDUSTRY

  • Cordis Corporation

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Medtronic

    collaborator INDUSTRY

  • Baim Institute for Clinical Research

    lead OTHER

Principal Investigators

  • Laura Mauri, MD, MSc · Brigham and Women's Hospital

  • Dean Kereiakes, MD, FACC · Christ Hospital Heart and Vascular Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Germany
  • Hungary
  • New Zealand
  • Poland
  • Romania
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00977938 on ClinicalTrials.gov